Tuoyi urothelial cancer indications national launch meeting in Chengdu ended

Expanding the future and benefiting the world - The National Launch of Tuoyi® Urothelial Carcinoma Indications will be held in Chengdu.
Thousands of urology experts from across the country gather to launch Tuoyi® (Treprizumab) Urothelial Cancer Indications As an opportunity, we will jointly discuss the current status and progress of diagnosis and treatment of urothelial cancer, and look forward to more breakthroughs in the immunotherapy of epithelial cancer and the treatment of urinary tumors in China
.

Professor Wei Qiang, co-chairman of the conference, vice chairman of the Chinese Medical Association Urology Branch, and director of the Department of Urology, West China Hospital of Sichuan University, delivered a welcome speech, thanking the experts for taking the time to come, and Academician Guo Yinglu, on behalf of the National Urological Cancer Research Center, expressed his warm welcome to the successful convening of the conference Congratulations
.
The chairman of the Chinese Medical Association Urology Branch and the chairman of the Congress of Professor Huang Jian from Sun Yat-sen Memorial Hospital of Sun Yat-sen University wished Tuoyi® urothelial carcinoma indications to be successfully listed, and cooperated with Professor Xing Nianzeng, Professor Ye Dingwei, Professor Zhang Xu, Professor Zhou Liqun, and Wei Professor Qiang, Professor He Zhisong, Ms.

Immunotherapy brings new hope, updated guidelines promote the progress of diagnosis and treatment

With the rise of research on immunotherapy, antibody-conjugated drugs, and targeted drugs, a lot of new clinical evidence has been generated, and the treatment of bladder cancer has also changed
.
Therefore, the diagnosis and treatment guidelines that guide doctors' clinical diagnosis work also need to be updated continuously to standardize the selection of bladder cancer diagnosis and treatment methods, and improve the level of diagnosis and treatment of bladder cancer

Professor Wei Qiang gave a keynote speech on “Considerations and Future Prospects of the Diagnosis and Treatment of Urothelial Carcinoma in China in the New Era of Immunity”.

Professor Mao Gantai, Director of the Pharmacy Department of Beijing Tsinghua Chang Gung Memorial Hospital, introduced the unique pharmacological mechanism of teriprizumab.

A new integrated diagnosis and treatment model for the whole process of bladder cancer management, benefiting patients and doctors

At present, various aspects of bladder cancer diagnosis and treatment such as screening, diagnosis, treatment, and follow-up have pain points that need to be solved urgently, including insufficient attention to the disease, poor patient testing experience, insufficient immunotherapy experience of urologists, and inability to guarantee long-term management Wait a minute
.
In order to optimize the diagnosis and treatment of bladder cancer and bring better diagnosis and treatment methods and experience to patients, relying on the China Bladder Cancer Alliance, the Integrated Bladder Cancer Center (IUCC) has officially started construction

After the introduction of the integrated model of the whole-process management of bladder cancer, Professor Jiang Haowen from the Department of Urology, Huashan Hospital, Fudan University shared the theme of "How can patients with advanced urothelial cancer benefit from immunotherapy".
He emphasized: The treatment options for patients after metastasis and recurrence of epithelial carcinoma are very limited.
Medical treatment mainly relies on chemotherapy.
As the only effective treatment method, the survival time and quality of life of patients need to be greatly improved
.
The rise of immunotherapy will change the urinary tract in the past 30 years The current status of skin cancer treatment brings more treatment options to patients, prolongs their survival time and guarantees a higher quality of life

Expanding the future, leading precision, getting the whole process, the development potential of the urology field is endless

In the urothelial cancer session and the prostate cancer session, it can be described as "big coffee talks".
Many urologists discussed more topics about the disease
.
In addition to sharing some classic patient cases and sharing valuable experience in the process of clinical and experimental exploration, the experts also analyzed and discussed more detailed diagnosis and treatment issues, and thought about more treatment options and overall management issues

In addition, nearly 300 national authority and county experts in the field of urology, as well as representatives of leading medical companies in the industry, attended the first China County Urinary Tumor Health Development Forum to jointly improve county-level urinary tumor prevention and control and diagnosis and treatment technologies, and discuss urinary tumor research, Cooperation on the construction of county-level urinary tumor ecosystems and other topics are of far-reaching significance to improving the level of diagnosis and treatment of urinary tumors in China
.
At the forum, many experts mentioned that they hope that multiple parties from the society can participate in the joint construction of the county urinary tumor medical ecology, so as to improve the screening rate, diagnostic capabilities and treatment standards of primary urinary tumors, and to achieve rapid development of disciplines, so that the people of the county will be at their doorsteps.

       After enthusiastic academic exchanges, the national launch meeting of Tuoyi® Urothelial Cancer Indications to expand the future and benefit the world was successfully concluded
.
The conference is a condensing and summary of the progress of diagnosis and treatment in the field of urology in China.
It provides a good opportunity for exchanges with many experts and organizations, and is highly praised and highly recognized by the participating experts
.
Professor Ye Dingwei, Chairman of the Committee of Urology and Male Reproductive Tumor Specialty Committee of Chinese Anti-Cancer Association, Vice President of Fudan University Tumor Hospital, and Professor Zhang Xu, Director-designate of Urology Branch of Chinese Medical Association, and Director of Department of Urology, PLA General Hospital, spoke to the conference In summary, the two chairmen affirmed the keynote speeches and academic discussions of the experts, and jointly stated that the development of immunotherapy in recent years is obvious to all.
The continuous development of immunotherapy will benefit more patients, and the improvement of the efficiency and level of diagnosis and treatment will also allow More and more doctors and other staff have benefited, and it is expected that future research and development results will contribute to tumor immunotherapy worldwide
.